| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 25.56 | 42.3% |
| Total Income | 25.56 | 42.3% |
| Expenditure | 31.76 | 17.2% |
| PBT | — | |
| Net Profit | -7.79 | 29.8% |
| OPM | -24.27% | 26.61pp |
| NPM | -30.50% | 31.32pp |
| EPS | -0.81 | 912.5% |
Biodesix Announces Q1 2026 Results: Revenue Up 42% to $25.6 Million
05 May 2026 · 5 May, 1:37 am
Summary
Biodesix announced its Q1 2026 financial results, reporting a 42% increase in total revenue to $25.6 million. Diagnostic Testing revenue grew by 37%, while Development Services revenue nearly doubled. The company's gross margin was 84%, or 82% excluding a one-time item, representing a 300-basis-point improvement year-over-year. Biodesix is raising its full-year 2026 revenue guidance to $108-114 million, reflecting confidence in continued growth and progress toward profitability.
Key Highlights
- 1
Biodesix's total revenue reached $25.6 million in Q1 2026, representing a 42% increase compared to the prior year.
- 2
Diagnostic Testing revenue grew by 37% year-over-year to $22.3 million, driven by a 29% increase in test volumes.
- 3
Development Services revenue saw a 99% increase year-over-year, reaching $3.3 million in Q1 2026.
- 4
The company achieved an 84% gross margin in Q1 2026, which includes a one-time recovery of $0.4 million related to previously paid sales and use taxes.
- 5
Excluding the one-time item, the gross margin was 82%, a 300-basis-point improvement over the prior year.
- 6
Biodesix is raising its full-year 2026 revenue guidance to $108-114 million, with the midpoint reflecting 25% growth.
- 7
The net loss for Q1 2026 improved by 30% over the prior year comparable period, amounting to a loss of $7.8 million.
Management Comments
Scott Hutton
"Biodesix delivered exceptional first quarter results that reflect strong momentum across both our Diagnostic Testing and our Development Services business." "Test volumes grew 29%, Development Services revenue doubled, and average revenue per test increased through expanded payer coverage and improved revenue cycle management, driving total revenue growth of 42% year over year. We were also recognized as a Top Workplace for the third consecutive year, reinforcing that our culture is not aspirational, its operational. Our first quarter results reflect a disciplined culture of execution in service to our partners, healthcare providers, and the patients they serve. With strong performance across both business lines and continued operational leverage, we are raising our full‑year 2026 guidance and remain on a clear path toward profitability."
Informational and educational content only. Not investment advice.